NCT00121680View on ClinicalTrials.gov

A Phase I/Ib, Multicenter, Open-Label, Dose Escalation Study of E7080 in Patients With Solid Tumors and in Combination With Temozolomide in Patients With Advanced and/or Metastatic Melanoma

PHASE1CompletedINTERVENTIONAL
Enrollment

115

Participants

Timeline

Start Date

July 31, 2005

Primary Completion Date

September 30, 2011

Study Completion Date

May 31, 2015

Conditions
Metastatic Melanoma
Interventions
DRUG

E7080

Oral.

Trial Locations (2)

Unknown

Dallas

Houston

All Listed Sponsors
lead

Eisai Inc.

INDUSTRY

NCT00121680 - A Phase I/Ib, Multicenter, Open-Label, Dose Escalation Study of E7080 in Patients With Solid Tumors and in Combination With Temozolomide in Patients With Advanced and/or Metastatic Melanoma | Biotech Hunter | Biotech Hunter